BioSpace News Archive

Researchers from Children’s Hospital of Philadelphia and University of Pennsylvania estimate the efficacy of social distancing

VALBIOTIS (Paris:ALVAL) (FR0013254851 - ALVAL, PEA/SME eligible) a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, announces the First Patient First Visit in the international Phase II/III REVERSE-IT clinical study designed to assess TOTUM-63 for the reduction of Type 2 Diabetes metabolic risk factors.

The New Facility Will Offer Convenient, Quick Access to Quality Emergency Room and Urgent Care in Hamilton County

I Peace, Inc. (CEO: Koji Tanabe, https://ipeace.com/), a Palo Alto-based biotech startup focusing on Nobel Prize-wining technology of induced pluripotent stem cells (iPSCs) has successfully developed a novel system to mass manufacture clinical-grade iPSCs for cell therapy in a palm-size closed cassette

CORPORATION TERRANUEVA (CSE : TEQ) (the “Corporation” or “Terranueva”) and Laboratoire LSL Inc. (“Laboratoire LSL”) announce that the parties have terminated their contractual relationship for the acquisition of the securities of Laboratoire LSL announced by press release on March 27, 2020.

The Battelle CCDS Critical Care Decontamination System™ (CCDS) passed both filtration efficiency and fit-related evaluations through 20 cycles for two different 3M respirators tested (models 1860 and 8210), with results published in 3M’s latest technical bulletin

Stronger growth and higher profitability expected for the Bioprocess Solutions Division and the entire Group; outlook for the Lab Products & Services Division unchanged

HealthEquity, Inc. (NASDAQ: HQY) (“HealthEquity” or the “Company”) today announced the closing of the underwritten public offering of an additional 690,000 shares of its common stock pursuant to the exercise in full by the underwriters of their over-allotment option

Medtronic Will Become the First Company to Offer an Integrated Solution Including Artificial Intelligence-Driven Surgical Planning, Personalized Spinal Implants and Robotic Assisted Surgery

Knopp Biosciences LLC announced that it has received Rare Pediatric Disease Designation from the U.S. Food and Drug Administration for its therapeutic candidate KB-3061, an activator of voltage-gated Kv7.2/7.3 potassium channels, for the treatment of KCNQ2 epileptic encephalopathy.